IP Library Granted Patent US 8,278,325
Granted Patent B2
US 8,278,325 · App. 13/186,351 · Granted Oct 2, 2012

Nitrogen-containing heteroaryl compounds and methods of use thereof

Assignee: FibroGen, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,278,325
App. No.
13/186,351
Granted
Oct 2, 2012
Kind
B2
Abstract

The present invention relates to compounds suitable for use in mediating hypoxia inducible factor and for treating erythropoietin-associated conditions by increasing endogenous erythropoietin in vitro and in vivo.

Claims (73)

1. A compound represented by formula:

wherein:

R 1 is selected from the group consisting of hydrogen, halo, alkyl, substituted alkyl, alkoxy, substituted alkoxy, amino, substituted amino, aminoacyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic, substituted heterocyclic, and —XR 6 where X is oxygen, —S(O) n — or —NR 7 — where n is zero, one or two, R 6 is selected from the group consisting of alkyl, substituted alkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic and substituted heterocyclic, and R 7 is hydrogen, alkyl or aryl or, when X is —NR 7 —, then R 7 and R 6 , together with the nitrogen atom to which they are bound, can be joined to form a heterocyclic or substituted heterocyclic group; and

R 2 and R 3 are independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, halo, hydroxy, cyano, —S(O) n —N(R 6 )—R 6 where n is 0, 1, or 2, —NR 6 C(O)NR 6 R 6 , and —XR 6 where X is oxygen, —S(O) n — or —NR 7 — where n is zero, one or two, each R 6 is independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, cycloalkyl, substituted cycloalkyl, heteroaryl, substituted heteroaryl, heterocyclic and substituted heterocyclic provided that when X is —SO— or —SO 2 —, then R 6 is not hydrogen, and R 7 is selected from the group consisting of hydrogen, alkyl, and aryl, or R 2 , R 3 together with the carbon atom pendent thereto, form an aryl substituted aryl, heteroaryl, or substituted heteroaryl;

or a pharmaceutically acceptable salt, ester, or amide thereof;

with the proviso that at least one of the following occurs:

1) R 1 is fluoro, bromo, iodo, alkyl, substituted alkyl, alkoxy, aminoacyl, substituted alkoxy, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic, substituted heterocyclic, or —XR 6 where X is oxygen, —S(O) n — or —NR 7 — where n is zero, one or two, R 6 is selected from the group consisting of alkyl, substituted alkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic and substituted heterocyclic, and R 7 is hydrogen, alkyl or aryl; or

2) R 2 is substituted alkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, fluoro, iodo, cyano, or —XR 6 where X is oxygen, —S(O) n — or —NR 7 — where n is zero, one or two, R 6 is selected from the group consisting of alkyl, substituted alkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic and substituted heterocyclic, and R 7 is hydrogen, alkyl or aryl provided that:

a) when R 2 is substituted alkyl such a substituent does not include trifluoromethyl;

b) —XR 6 is not alkoxy; and

c) when —XR 6 is substituted alkoxy such a substituent does not include benzyl or benzyl substituted by a substituent selected from the group consisting of (C 1 -C 5 ) alkyl and (C 1 -C 5 ) alkoxy or does not include a fluoroalkoxy substituent of the formula:

—O—[CH 2 ] x —C f H (2f+1−g) F g

where x is zero or one; f is an integer of from 1 to 5; and g is an integer of from 1 to (2f+1); or

3) R 3 is substituted alkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, bromo, iodo, or —XR 6 where X is oxygen, —S(O) n — or —NR 7 — where n is zero, one or two, R 6 is selected from the group consisting of alkyl, substituted alkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic and substituted heterocyclic, and R 7 is hydrogen, alkyl or aryl provided that:

a) when R 3 is substituted alkyl such a substituent does not include trifluoromethyl;

b) —XR 6 is not alkoxy; and

c) when —XR 6 is substituted alkoxy such a substituent does not include benzyl or benzyl substituted by a substituent selected from the group consisting of (C 1 -C 5 ) alkyl and (C 1 -C 5 ) alkoxy or does not include a fluoroalkoxy substituent of the formula:

—O—[CH 2 ] x —C f H (2f+1−g) F g

where x is zero or one; f is an integer of from 1 to 5; and g is an integer of from 1 to (2f+1).

2. The compound of claim 1 , wherein:

R 2 and R 3 are independently selected from the group consisting of hydrogen and —XR 6 where X is oxygen or sulfur, and each R 6 is independently selected from the group consisting of aryl and substituted aryl;

with the proviso that at least one of the following occurs:

1) R 1 is fluoro, bromo, iodo, alkyl, substituted alkyl, alkoxy, aminoacyl, substituted alkoxy, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic, substituted heterocyclic, or —XR 6 where X is oxygen, —S(O) n — or —NR 7 — where n is zero, one or two, R 6 is selected from the group consisting of alkyl, substituted alkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic and substituted heterocyclic, and R 7 is hydrogen, alkyl or aryl;

2) R 2 is —XR 6 where X is oxygen or sulfur, and R 6 is selected from the group consisting of aryl and substituted aryl; or

3) R 3 is —XR 6 where X is oxygen or sulfur, and R 6 is selected from the group consisting of aryl and substituted aryl.

3. The compound of claim 1 , wherein:

R 2 and R 3 are independently selected from the group consisting of hydrogen and —XR 6 where X is oxygen or sulfur, each R 6 is independently selected from the group consisting of aryl, and substituted aryl;

with the proviso that at least one of the following occurs:

1) R 2 is —XR 6 where X is oxygen or sulfur and R 6 is selected from the group consisting of aryl and substituted aryl; or

2) R 3 is —XR 6 where X is oxygen or sulfur and R 6 is selected from the group consisting of aryl and substituted aryl.

4. The compound of claim 1 , wherein:

R 2 is —XR 6 where X is oxygen or sulfur, and R 6 is aryl or aryl substituted with one or two substituents independently selected from the group consisting of halo, alkyl, alkyl substituted with up to three halo substituents, alkoxy, alkoxy substituted with up to three halo substituents, nitro, alkylsulfonamido, and arylsulfonamido; and

R 3 is hydrogen.

5. The compound of claim 4 , wherein R 1 is selected from the group consisting of hydrogen, halo and alkyl.

6. A pharmaceutical composition comprising

one or more compounds of claim 1 or a pharmaceutically acceptable salt, ester, or amide thereof and

a pharmaceutically acceptable carrier or excipient.

7. The pharmaceutical composition of claim 6 , wherein the compound is of the formula:

or a pharmaceutically acceptable salt, ester, or amide thereof.

8. The pharmaceutical composition of claim 6 , wherein the compound is of the formula:

or a pharmaceutically acceptable salt, ester, or amide thereof.

9. The pharmaceutical composition of claim 6 , wherein the compound is of the formula:

or a pharmaceutically acceptable salt, ester, or amide thereof.

10. The pharmaceutical composition of claim 6 , wherein the compound is of the formula:

or a pharmaceutically acceptable salt, ester, or amide thereof.

11. The pharmaceutical composition of claim 6 , wherein the compound is of the formula:

or a pharmaceutically acceptable salt, ester, or amide thereof.

12. The pharmaceutical composition of claim 6 , wherein the compound is of the formula:

or a pharmaceutically acceptable salt, ester, or amide thereof.

13. The pharmaceutical composition of claim 6 , wherein the compound is of the formula:

or a pharmaceutically acceptable salt, ester, or amide thereof.

14. The pharmaceutical composition of claim 6 , wherein the compound is of the formula:

or a pharmaceutically acceptable salt, ester, or amide thereof.

15. The pharmaceutical composition of claim 6 , wherein the compound is of the formula:

or a pharmaceutically acceptable salt, ester, or amide thereof.

16. The pharmaceutical composition of claim 6 , wherein the compound is of the formula:

or a pharmaceutically acceptable salt, ester, or amide thereof.

17. The pharmaceutical composition of claim 6 , wherein the compound is of the formula:

or a pharmaceutically acceptable salt, ester, or amide thereof.

18. The pharmaceutical composition of claim 6 , wherein the compound is of the formula:

or a pharmaceutically acceptable salt, ester, or amide thereof.

19. The pharmaceutical composition of claim 6 , wherein the compound is of the formula:

or a pharmaceutically acceptable salt, ester, or amide thereof.

20. The pharmaceutical composition of claim 6 , wherein the compound is of the formula:

or a pharmaceutically acceptable salt, ester, or amide thereof.

21. The pharmaceutical composition of claim 6 , wherein the compound is of the formula:

or a pharmaceutically acceptable salt, ester, or amide thereof.

22. The pharmaceutical composition of claim 6 , wherein the compound is of the formula:

or a pharmaceutically acceptable salt, ester, or amide thereof.

23. The pharmaceutical composition of claim 6 , wherein the compound is of the formula:

or a pharmaceutically acceptable salt, ester, or amide thereof.

24. The pharmaceutical composition of claim 6 , wherein the compound is of the formula:

or a pharmaceutically acceptable salt, ester, or amide thereof.

Assignments (3)
RELEASE OF SECURITY INTEREST Recorded Sep 3, 2025
From: WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT
To: FIBROGEN, INC.
Reel/Frame 072785/0760 →
SECURITY INTEREST Recorded May 1, 2023
From: FIBROGEN, INC.
To: WILMINGTON TRUST, NATIONAL ASSOCIATION
Reel/Frame 063504/0221 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 15, 2012
From: AREND, MICHAEL P.; FLIPPIN, LEE A.; GUENZLER-PUKALL, VOLKMAR; HO, WEN-BIN; TURTLE, ERIC D.; DU, XIAOHUI
To: FIBROGEN, INC.
Reel/Frame 028387/0511 →
Continuity (7)
Continuation 12015275 · Jan 16, 2008
Division 10861082 · Jun 4, 2004
Provisional Application 60476811 · Jun 6, 2003
Provisional Application 60476420 · Jun 6, 2003
Provisional Application 60476633 · Jun 6, 2003
Provisional Application 60476519 · Jun 6, 2003
Related Publication 20120029011A1 · Feb 2, 2012